Base de dados : MEDLINE
Pesquisa : D02.886.675 [Categoria DeCS]
Referências encontradas : 27858 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2786 ir para página                         

  1 / 27858 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376612
[Au] Autor:Kasyan GR; Sukhikh SO; Pushkar DY
[Ad] Endereço:Department of Urology, A.I. Evdokimov MSUMD, Moscow, Russia.
[Ti] Título:[The place of mirabegron in clinical practice].
[So] Source:Urologiia;(6):144-148, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Currently, a wide range of different drugs is available for te management of overactive bladder. This creates problems when it comes to drug selection and personalized care for each patient. Mirabegron is the only 3-adrenomimetic agent for the treatment of urinary disorders, which, after careful long-term multi-center randomized trials, has been approved for use in Europe and North America. Mirabegron has proven to be very effective in patients who had previously received anticholinergic drugs and discontinued them because of the insufficient therapeutic effect or pronounced adverse reactions. However, the question of using Mirabegron as a first-line treatment for overactive bladder and the existing limitations in its administration in clinical urology practice remains open.
[Mh] Termos MeSH primário: Acetanilidas/efeitos adversos
Acetanilidas/uso terapêutico
Tiazóis/efeitos adversos
Tiazóis/uso terapêutico
Bexiga Urinaria Neurogênica/tratamento farmacológico
Incontinência Urinária/tratamento farmacológico
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
Bexiga Urinaria Neurogênica/fisiopatologia
Incontinência Urinária/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Acetanilides); 0 (Thiazoles); MVR3JL3B2V (mirabegron)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  2 / 27858 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29272749
[Au] Autor:Liessi N; Cichero E; Pesce E; Arkel M; Salis A; Tomati V; Paccagnella M; Damonte G; Tasso B; Galietta LJV; Pedemonte N; Fossa P; Millo E
[Ad] Endereço:Department of Experimental Medicine, Section of Biochemistry, University of Genoa, Viale Benedetto XV 1, 16132 Genoa, Italy; Center of Excellence for Biomedical Research (CEBR), University of Genoa, Viale Benedetto XV 9, 16132 Genoa, Italy.
[Ti] Título:Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools.
[So] Source:Eur J Med Chem;144:179-200, 2018 Jan 20.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:The most common CF mutation, F508del, impairs the processing and gating of CFTR protein. This deletion results in the improper folding of the protein and its degradation before it reaches the plasma membrane of epithelial cells. Present correctors, like VX809 only induce a partial rescue of the mutant protein. Our previous studies reported a class of compounds, called aminoarylthiazoles (AATs), featuring an interesting activity as correctors. Some of them show additive effect with VX809 indicating a different mechanism of action. In an attempt to construct more interesting molecules, it was thought to generate chemically hybrid compounds, blending a portion of VX809 merged to the thiazole scaffold. This approach was guided by the development of QSAR analyses, which were performed based on the F508del correctors so far disclosed in the literature. This strategy was aimed at exploring the key requirements turning in the corrector ability of the collected derivatives and allowed us to derive a predictive model guiding for the synthesis of novel hybrids as promising correctors. The new molecules were tested in functional and biochemical assays on bronchial CFBE41o-cells expressing F508del-CFTR showing a promising corrector activity.
[Mh] Termos MeSH primário: Aminopiridinas/química
Aminopiridinas/farmacologia
Benzodioxóis/química
Benzodioxóis/farmacologia
Regulador de Condutância Transmembrana em Fibrose Cística/genética
Mutação/efeitos dos fármacos
Tiazóis/química
Tiazóis/farmacologia
[Mh] Termos MeSH secundário: Aminopiridinas/síntese química
Benzodioxóis/síntese química
Linhagem Celular
Fibrose Cística/tratamento farmacológico
Fibrose Cística/genética
Seres Humanos
Relação Quantitativa Estrutura-Atividade
Tiazóis/síntese química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aminopyridines); 0 (Benzodioxoles); 0 (Thiazoles); 126880-72-6 (Cystic Fibrosis Transmembrane Conductance Regulator); EGP8L81APK (lumacaftor)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171223
[St] Status:MEDLINE


  3 / 27858 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29248751
[Au] Autor:Can NÖ; Osmaniye D; Levent S; Saglik BN; Korkut B; Atli Ö; Özkay Y; Kaplancikli ZA
[Ad] Endereço:Department of Analytical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskisehir, Turkey; Doping and Narcotic Compounds Analysis Laboratory, Faculty of Pharmacy, Anadolu University, 26470 Eskisehir, Turkey.
[Ti] Título:Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible hMAO-A inhibitors.
[So] Source:Eur J Med Chem;144:68-81, 2018 Jan 20.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:In the recent works, it was shown that numerous thiazolylhydrazine derivatives display hMAO inhibitory activity in the range of micromolar concentration. Hence, in the present study a new series of new thiazole-hydrazines (3a-3n) were designed, synthesized, characterized and screened for their hMAO-A and hMAO-B inhibitory activity by an in vitro flurometric method. The enzyme inhibition assay revealed that most of the synthesized compounds have selective inhibition potency against hMAO-A. The compounds 3f and 3h showed promising hMAO-A inhibition with an IC values of 0.012 µM and 0.011 µM and significant selectivity indexes of 1214 and 1601 towards hMAO-A, respectively. The mechanism of hMAO-A inhibition of compounds 3f and 3h was investigated by Lineweaver-Burk graphics and reversible-competitive inhibition of hMAO-A was determined. Cytotoxicity and genotoxicity studies were carried out and the compound 3h was found as non-cytotoxic and non-genotoxic. Theoretical calculation of ADME properties suggested that synthesized compounds may have a good pharmacokinetic profile. The docking study of compound 3f and 3h revealed that there is a strong interaction between the active sites of hMAO-A and analyzed compound.
[Mh] Termos MeSH primário: Inibidores da Monoaminoxidase/química
Inibidores da Monoaminoxidase/farmacologia
Monoaminoxidase/metabolismo
Tiazóis/química
Tiazóis/farmacologia
[Mh] Termos MeSH secundário: Domínio Catalítico/efeitos dos fármacos
Desenho de Drogas
Seres Humanos
Hidrazinas/química
Hidrazinas/farmacologia
Simulação de Acoplamento Molecular
Monoaminoxidase/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hydrazines); 0 (Monoamine Oxidase Inhibitors); 0 (Thiazoles); EC 1.4.3.4 (Monoamine Oxidase)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171218
[St] Status:MEDLINE


  4 / 27858 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:29267503
[Au] Autor:Wang ZK; Yang L; Wu LL; Mao H; Zhou YH; Zhang PF; Dai GH
[Ad] Endereço:The Second Department of Medical Oncology, Chinese People's Liberation Army General Hospital, Beijing, China.
[Ti] Título:Long non-coding RNA LINC00261 sensitizes human colon cancer cells to cisplatin therapy.
[So] Source:Braz J Med Biol Res;51(2):e6793, 2017 Dec 11.
[Is] ISSN:1414-431X
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Colon cancer is one of the most common digestive tumors. The present study aimed to explore the functional role, as well as the underlying mechanism of long non-coding RNA LINC00261 in colon cancer. Expression of LINC00261 was analyzed in colon cancer cell lines and human normal cell lines. Acquired resistance cell lines were then built and the acquired resistance efficiency was detected by evaluating cell viability. Thereafter, the effects of LINC00261 overexpression on cisplatin-resistant colon cancer cells were measured, as well as cell apoptosis, viability, migration, and invasion. Subsequently, we investigated the interaction of LINC00261 and ß-catenin. The results showed that the LINC00261 gene was down-regulated in colon cancer cell lines and tissues, and in cisplatin-resistant cells. LINC00261 overexpression might relieve cisplatin resistance of colon cancer cells via promoting cell apoptosis, and inhibiting cell viability, migration, and invasion. Moreover, LINC00261 might down-regulate nuclear ß-catenin through restraining ß-catenin from cytoplasm into nuclei or it could also promote ß-catenin degradation and inhibit activation of Wnt pathway. Finally, LINC00261 reduced cisplatin resistance of colon cancer in vivo and enhanced the anti-colon cancer effect of cisplatin through reducing tumor volume and weight.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Cisplatino/farmacologia
Neoplasias do Colo/tratamento farmacológico
Neoplasias do Colo/genética
Neoplasias do Colo/patologia
RNA Longo não Codificante/fisiologia
[Mh] Termos MeSH secundário: Análise de Variância
Apoptose/efeitos dos fármacos
Apoptose/fisiologia
Proteínas Reguladoras de Apoptose/efeitos dos fármacos
Proteínas Reguladoras de Apoptose/fisiologia
Western Blotting
Ensaios de Migração Celular
Proliferação Celular/efeitos dos fármacos
Proliferação Celular/fisiologia
Regulação para Baixo
Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos
Regulação Neoplásica da Expressão Gênica/fisiologia
Células HCT116
Células HT29
Seres Humanos
RNA Longo não Codificante/análise
RNA Longo não Codificante/efeitos dos fármacos
RNA Longo não Codificante/genética
Reprodutibilidade dos Testes
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Transdução de Sinais/efeitos dos fármacos
Transdução de Sinais/fisiologia
Sais de Tetrazólio
Tiazóis
beta Catenina/efeitos dos fármacos
beta Catenina/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Apoptosis Regulatory Proteins); 0 (RNA, Long Noncoding); 0 (Tetrazolium Salts); 0 (Thiazoles); 0 (beta Catenin); 0 (long non-coding RNA 00261, human); EUY85H477I (thiazolyl blue); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE


  5 / 27858 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28942278
[Au] Autor:Demirci Ö; Güven K; Asma D; Ögüt S; Ugurlu P
[Ad] Endereço:Science Faculty, Department of Biology, Dicle University, 21280, Turkey. Electronic address: ozdem22@gmail.com.
[Ti] Título:Effects of endosulfan, thiamethoxam, and indoxacarb in combination with atrazine on multi-biomarkers in Gammarus kischineffensis.
[So] Source:Ecotoxicol Environ Saf;147:749-758, 2018 Jan.
[Is] ISSN:1090-2414
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Studies addressing the toxicity of pesticides towards non-target organisms focus on the median lethal concentration and biochemical response of individual pesticides. However, when determining environmental risks, it is important to test the combined effects of pesticides, such as insecticides and herbicides, which are frequently used together in agricultural areas. Here we aimed to investigate the toxic effects of the combined use of the herbicide atrazine and the insecticides, endosulfan, indoxacarb, and thiamethoxam on Gammarus kischineffensis. To do this, we tested the activities of oxidative stress, detoxification, and neurotoxicity biomarkers. Compared to atrazine alone, we detected higher glutathione-S-transferase, catalase and superoxide dismutase activities (oxidative stress biomarkers) when atrazine was combined with either endosulfan or indoxacarb. However, higher IBR values were determined in organisms where pesticide mixtures were used according to individual use. Based on these results, mixtures of atrazine and other pesticides may cause synergistic effects and may be evidence of increased toxicity and oxidative stress.
[Mh] Termos MeSH primário: Anfípodes/efeitos dos fármacos
Monitoramento Ambiental/métodos
Herbicidas/toxicidade
Inseticidas/toxicidade
Poluentes do Solo/toxicidade
[Mh] Termos MeSH secundário: Anfípodes/enzimologia
Animais
Atrazina/toxicidade
Biomarcadores/análise
Relação Dose-Resposta a Droga
Sinergismo Farmacológico
Endossulfano/toxicidade
Dose Letal Mediana
Neonicotinoides/toxicidade
Nitrocompostos/toxicidade
Oxazinas/toxicidade
Estresse Oxidativo/efeitos dos fármacos
Tiazóis/toxicidade
Fatores de Tempo
Testes de Toxicidade Aguda
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Herbicides); 0 (Insecticides); 0 (Neonicotinoids); 0 (Nitro Compounds); 0 (Oxazines); 0 (Soil Pollutants); 0 (Thiazoles); 52H0D26MWR (indoxacarb); 747IC8B487 (thiamethoxam); OKA6A6ZD4K (Endosulfan); QJA9M5H4IM (Atrazine)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170925
[St] Status:MEDLINE


  6 / 27858 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:29412221
[Au] Autor:Daniela Ferreira Araújo B; Luciana Oliveira P; Izabel Cristina Rodrigues da S; Ricardo Bentes A; Ana Cristina Barreto B
[Ad] Endereço:Universidade de Brasília - UnB, Institute of Biological Sciences, Laboratory of Nanobiotechnology, Brasília, DF, Brazil.
[Ti] Título:Culture of human dental pulp cells at variable times post-tooth extraction.
[So] Source:Braz Oral Res;32:e003, 2018 Feb 01.
[Is] ISSN:1807-3107
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:The aim of this study was to investigate the viability of human dental pulp cells from extracted teeth kept at standard room temperature and atmospheric pressure for different periods of time. Twenty-one healthy permanent teeth were used. They were divided into five groups according to the expected time from extraction to processing. One group was tested immediately after extraction; the other groups were each tested at one of the following time points: 30 minutes, 1 hour, 2 hours, and 5 hours post-extraction. Cell morphology was analysed by light microscopy; cell proliferation was analysed using MTT assay and by counting the viable cells in a haemocytometer. Similar results were observed in all groups (p < 0.05). A delay of up to five hours for tooth processing and tissue collection does not preclude the establishment of dental pulp cell cultures, affect the morphology of these cells, or reduce their proliferative potential.
[Mh] Termos MeSH primário: Técnicas de Cultura de Células/métodos
Polpa Dentária/citologia
Extração Dentária
[Mh] Termos MeSH secundário: Análise de Variância
Contagem de Células
Proliferação Celular
Sobrevivência Celular
Células Cultivadas
Meios de Cultura
Seres Humanos
Reprodutibilidade dos Testes
Sais de Tetrazólio
Tiazóis
Fatores de Tempo
Preservação de Tecido/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Culture Media); 0 (Tetrazolium Salts); 0 (Thiazoles); EUY85H477I (thiazolyl blue)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:D; IM
[Da] Data de entrada para processamento:180208
[St] Status:MEDLINE


  7 / 27858 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29318298
[Au] Autor:Jukic M; Grabrijan K; Kadic S; Lera Garrido FJ; Sosic I; Gobec S; Obreza A
[Ti] Título:Chlorocarbonylsulfenyl Chloride Cyclizations Towards Piperidin-3-yl-oxathiazol-2-ones as Potential Covalent Inhibitors of Threonine Proteases.
[So] Source:Acta Chim Slov;64(4):771-781, 2017 Dec.
[Is] ISSN:1318-0207
[Cp] País de publicação:Slovenia
[La] Idioma:eng
[Ab] Resumo:Using rescaffolding approach, we designed piperidine compounds decorated with an electrophilic oxathiazol-2-one moiety that is known to confer selectivity towards threonine proteases. Our efforts to prepare products according to the published procedures were not successful. Furthermore we identified major side products containing nitrile functional group, resulting from carboxamide dehydration. We systematically optimized reaction conditions towards our desired products to identify heating of carboxamides with chlorocarbonylsulfenyl chloride and sodium carbonate as base in dioxane at 100 °C. Our efforts culminated in the preparation of a small series of piperidin-3-yl-oxathiazol-2-ones that are suitable for further biological evaluation.
[Mh] Termos MeSH primário: Piperidinas/química
Inibidores de Proteases/síntese química
Tiazóis/química
Treonina/metabolismo
[Mh] Termos MeSH secundário: Ciclização
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Piperidines); 0 (Protease Inhibitors); 0 (Thiazoles); 2ZD004190S (Threonine)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE


  8 / 27858 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29355909
[Au] Autor:Temmingh HS; Williams T; Siegfried N; Stein DJ
[Ad] Endereço:Department of Psychiatry and Mental Health, University of Cape Town, Valkenberg Hospital, Private Bage X1, Cape Town, Western Cape, South Africa, 7935.
[Ti] Título:Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
[So] Source:Cochrane Database Syst Rev;1:CD011057, 2018 Jan 22.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Up to 75% of people with serious mental illness (SMI) such as schizophrenia and bipolar disorder have co-occurring substance use disorders (dual diagnosis). Dual diagnosis can have an adverse effect on treatment and prognosis of SMI. OBJECTIVES: To evaluate the effects of risperidone compared to treatment with other antipsychotics (first-generation and other second-generation antipsychotics) used in people with serious mental illness and co-occurring substance misuse. SEARCH METHODS: On 6 January 2016 and 9 October 2017, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (including trial registers). SELECTION CRITERIA: We selected randomised trials of risperidone versus any other antipsychotic in people with SMI and substance abuse (dual diagnosis). We included trials meeting our inclusion criteria and reporting useable data. We excluded trials that either did not meet our inclusion criteria or met our inclusion criteria but did not report any useable data. DATA COLLECTION AND ANALYSIS: We independently inspected citations and selected studies. For included studies, we independently extracted data and appraised study quality. For binary outcomes we calculated the risk ratios (RRs) and their 95% confidence intervals. For continuous outcomes we calculated the mean differences (MDs) and their 95% confidence intervals. We pooled data using random-effects meta-analyses and assessed the quality of evidence, creating a 'Summary of findings' table using the GRADE approach. MAIN RESULTS: We identified eight randomised trials containing a total of 1073 participants with SMI and co-occurring substance misuse. Seven of these contributed useable data to the review. There was heterogeneity in trial design and measurement. Risperidone was compared to clozapine, olanzapine, perphenazine, quetiapine and ziprasidone. Few trials compared risperidone with first-generation agents. Few trials examined participants with a dual diagnosis from the outset and most trials only contained separate analyses of subgroups with a dual diagnosis or were secondary data analyses of subgroups of people with a dual diagnosis from existing larger trials.For risperidone versus clozapine we found no clear differences between these two antipsychotics in the reduction of positive psychotic symptoms (1 randomised controlled trial (RCT), n = 36, mean difference (MD) 0.90, 95% CI -2.21 to 4.01, very low quality evidence), or reduction in cannabis use (1 RCT, n = 14, risk ratio (RR) 1.00, 95% CI 0.30 to 3.35, very low quality evidence), improvement in subjective well-being (1 RCT, n = 36, MD -6.00, 95% CI -14.82 to 2.82, very low quality evidence), numbers discontinuing medication (1 RCT, n = 36, RR 4.05, 95% CI 0.21 to 78.76, very low quality evidence), extrapyramidal side-effects (2 RCTs, n = 50, RR 2.71, 95% CI 0.30 to 24.08; I² = 0%, very low quality evidence), or leaving the study early (2 RCTs, n = 45, RR 0.49, 95% CI 0.10 to 2.51; I² = 34%, very low quality evidence). Clozapine was associated with lower levels of craving for cannabis (1 RCT, n = 28, MD 7.00, 95% CI 2.37 to 11.63, very low quality evidence).For risperidone versus olanzapine we found no clear differences in the reduction of positive psychotic symptoms (1 RCT, n = 37, MD -1.50, 95% CI -3.82 to 0.82, very low quality evidence), reduction in cannabis use (1 RCT, n = 41, MD 0.40, 95% CI -4.72 to 5.52, very low quality evidence), craving for cannabis (1 RCT, n = 41, MD 5.00, 95% CI -4.86 to 14.86, very low quality evidence), parkinsonism (1 RCT, n = 16, MD -0.08, 95% CI -1.21 to 1.05, very low quality evidence), or leaving the study early (2 RCT, n = 77, RR 0.68, 95% CI 0.34 to 1.35; I² = 0%, very low quality evidence).For risperidone versus perphenazine, we found no clear differences in the number of participants leaving the study early (1 RCT, n = 281, RR 1.05, 95% CI 0.92 to 1.20, low-quality evidence).For risperidone versus quetiapine, we found no clear differences in the number of participants leaving the study early (1 RCT, n = 294, RR 0.96, 95% CI 0.86 to 1.07, low-quality evidence).For risperidone versus ziprasidone, we found no clear differences in the number of participants leaving the study early (1 RCT, n = 240, RR 0.96, 95% CI 0.85 to 1.10, low-quality evidence).For many comparisons, important outcomes were missing; and no data were reported in any study for metabolic disturbances, global impression of illness severity, quality of life or mortality. AUTHORS' CONCLUSIONS: There is not sufficient good-quality evidence available to determine the effects of risperidone compared with other antipsychotics in people with a dual diagnosis. Few trials compared risperidone with first-generation agents, leading to limited applicability to settings where access to second-generation agents is limited, such as in low- and middle-income countries. Moreover, heterogeneity in trial design and measurement of outcomes precluded the use of many trials in our analyses. Future trials in this area need to be sufficiently powered but also need to conform to consistent methods in study population selection, use of measurement scales, definition of outcomes, and measures to counter risk of bias. Investigators should adhere to CONSORT guidelines in the reporting of results.
[Mh] Termos MeSH primário: Antipsicóticos/uso terapêutico
Transtornos Mentais/tratamento farmacológico
Risperidona/uso terapêutico
Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológico
[Mh] Termos MeSH secundário: Benzodiazepinas/uso terapêutico
Clozapina/uso terapêutico
Diagnóstico Duplo (Psiquiatria)
Seres Humanos
Pacientes Desistentes do Tratamento/estatística & dados numéricos
Perfenazina/uso terapêutico
Piperazinas/uso terapêutico
Fumarato de Quetiapina/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Esquizofrenia/tratamento farmacológico
Transtornos Relacionados ao Uso de Substâncias/psicologia
Tiazóis/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antipsychotic Agents); 0 (Piperazines); 0 (Thiazoles); 12794-10-4 (Benzodiazepines); 2S3PL1B6UJ (Quetiapine Fumarate); 6UKA5VEJ6X (ziprasidone); FTA7XXY4EZ (Perphenazine); J60AR2IKIC (Clozapine); L6UH7ZF8HC (Risperidone); N7U69T4SZR (olanzapine)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180123
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD011057.pub2


  9 / 27858 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29335206
[Au] Autor:Ayati A; Esmaeili R; Moghimi S; Oghabi Bakhshaiesh T; Eslami-S Z; Majidzadeh-A K; Safavi M; Emami S; Foroumadi A
[Ad] Endereço:Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
[Ti] Título:Synthesis and biological evaluation of 4-amino-5-cinnamoylthiazoles as chalcone-like anticancer agents.
[So] Source:Eur J Med Chem;145:404-412, 2018 Feb 10.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:A series of 4-amino-5-cinnamoylthiazoles 3a-p were designed and synthesized as chalcone-like anticancer agents. The synthesized derivatives 3a-p were evaluated for their in vitro antiproliferative activities against three different human cancer cell lines including MCF-7, HepG2 and SW480. Most of compounds could significantly prevent proliferation of tested cell lines. In particular, the pyrrolidine derivative 3e namely (E)-1-(4-amino-2-(pyrrolidin-1-yl)thiazol-5-yl)-3-(2,4-dichlorophenyl)prop-2-en-1-one showed promising activity, especially against HepG2 cells (IC = 10.6 µg/ml). Flow cytometric analyses revealed that the prototype compound 3e can prevent the proliferation of HepG2 cells by blockade of the cell cycle at the G2 phase and induction of apoptosis.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Tiazóis/farmacologia
[Mh] Termos MeSH secundário: Antineoplásicos/síntese química
Antineoplásicos/química
Apoptose/efeitos dos fármacos
Ciclo Celular/efeitos dos fármacos
Linhagem Celular Tumoral
Proliferação Celular/efeitos dos fármacos
Relação Dose-Resposta a Droga
Ensaios de Seleção de Medicamentos Antitumorais
Seres Humanos
Estrutura Molecular
Relação Estrutura-Atividade
Tiazóis/síntese química
Tiazóis/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Thiazoles)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE


  10 / 27858 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29329071
[Au] Autor:de Santana TI; Barbosa MO; Gomes PATM; da Cruz ACN; da Silva TG; Leite ACL
[Ad] Endereço:Departamento de Antibióticos, Centro de Biociências, Universidade Federal de Pernambuco, 50740-520, Recife, PE, Brazil.
[Ti] Título:Synthesis, anticancer activity and mechanism of action of new thiazole derivatives.
[So] Source:Eur J Med Chem;144:874-886, 2018 Jan 20.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Thiazole derivatives are recognized to possess various biological activities as antiparasitic, antifungal, antimicrobial and antiproliferative. The present work reports the synthesis of 22 new substances belonging to two classes of compounds: thiosemicarbazones and thiazoles, with the purpose of developing new drugs that present high specificity for tumor cells and low toxicity to the organism. A cytotoxic screening was performed to evaluate the performance of the new derivatives in five tumor cell lines. Eight compounds were shown to be promising in at least three tumor cell lines. These compounds had their IC determined within 72 h and the activity structure ratio was assessed. The effect of the best compounds on PBMC and hemolytic activity assay was then evaluated. The compound 1d was considered the most promising among the samples tested and its influence on cell cycle, DNA fragmentation and mitochondrial depolarization was evaluated.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Tiazóis/farmacologia
[Mh] Termos MeSH secundário: Antineoplásicos/síntese química
Antineoplásicos/química
Proliferação Celular/efeitos dos fármacos
Relação Dose-Resposta a Droga
Ensaios de Seleção de Medicamentos Antitumorais
Hemólise/efeitos dos fármacos
Seres Humanos
Estrutura Molecular
Relação Estrutura-Atividade
Tiazóis/síntese química
Tiazóis/química
Células Tumorais Cultivadas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Thiazoles)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE



página 1 de 2786 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde